Filtered By:
Drug: Pradaxa
Nutrition: Vitamins
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 482 results found since Jan 2013.
Factors associated with non –vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
Conclusions In contemporary clinical practice, up to three-fourths of patients with new-onset AF are now initially treated with a NOAC for stroke prevention. Those selected for NOAC treatment had lower stroke and bleeding risk profiles, were more likely treated by cardiologists, and had higher socioeconomic status. Trial registration clinicaltrials.gov Identifier: NCT01701817
Source: American Heart Journal - April 25, 2017 Category: Cardiology Source Type: research
Medium to long-term persistence with non-vitamin K oral anticoagulants in patients with atrial fibrillation: Australian experience.
CONCLUSIONS: Long-term persistence with anticoagulation in patients with AF remains a concern, even with NOACs. Patients initiated to apixaban appear to experience better medium-term persistence compared with rivaroxaban or dabigatran.
PMID: 28425296 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - April 22, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research
Role of Direct Oral Anticoagulants in the Management of Anticoagulation.
This article reviews the roles of dabigatran, rivaroxaban, apixaban, and edoxaban in stroke prevention in nonvalvular atrial fibrillation, for prevention of venous thromboembolism after orthopedic surgery, and in the treatment of venous thromboembolism. Direct oral anticoagulants are at least as efficacious and safe as traditional anticoagulation therapy.
PMID: 28376529 [PubMed - in process]
Source: Southern Medical Journal - April 6, 2017 Category: Journals (General) Tags: South Med J Source Type: research
Factors Associated with Non-vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with New-Onset Atrial Fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
Conclusions In contemporary clinical practice up to three-fourths of patients with new-onset AF are now initially treated with a NOAC for stroke prevention. Those selected for NOAC treatment had lower stroke and bleeding risk profiles, were more likely treated by cardiologists and had higher socioeconomic status. Trial Registration clinicaltrials.gov Identifier: NCT01701817
Source: American Heart Journal - April 4, 2017 Category: Cardiology Source Type: research
Use of idarucizumab for dabigatran reversal in patients with non-valvular atrial fibrillation undergoing emergency surgical repair of strangulated femoral hernia
We report a case of a 61-year-old woman with history of NVAF on dabigatran, presented to the emergency department with a strangulated right femoral hernia causing small bowel obstruction, where idarucizumab was administered before surgery. The patient had received her last dose of dabigatran 4 hours before presenting to the emergency department and her activated partial thromboplastin time was over the upper limit of reference. Surgery followed about one hour after the administration of idarucizumab and surgeon reported normal perioperative haemostasis. The patient had a normal recovery, received parenteral anticoagulation...
Source: Hellenic Journal of Surgery - April 1, 2017 Category: Surgery Source Type: research
Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants.
ConclusionsThere is a twofold increase of the risk for AMI for DOACs, in comparison with VKAs in AF therapy. In addition results suggest that in patients with AF, during aspirin monotherapy, incidence of AMI is higher than during the use of VKAs.
Source: British Journal of Clinical Pharmacology - March 23, 2017 Category: Drugs & Pharmacology Authors: Leo M. Stolk, Frank Vries, Chiel Ebbelaar, Anthonius Boer, Tom Schalekamp, Patrick Souverein, Arina Cate ‐Hoek, Andrea M. Burden Tags: PHARMACOEPIDEMIOLOGY Source Type: research
Dabigatran: Important Considerations in the Elderly
We read, with keen interest, the report by Dezman et al. regarding the severity of bleeding and mortality in trauma patients taking dabigatran (1). Stroke physicians frequently prescribe non-vitamin K antagonist oral anticoagulants (NOAC) like dabigatran for stroke prevention in the context of nonvalvular atrial fibrillation. Although the introducti on of NOAC into clinical practice has been a major advance with reduction of monitoring requirement, there remains ongoing concern about the risk of bleeding and the absence of an antidote.
Source: The Journal of Emergency Medicine - March 23, 2017 Category: Emergency Medicine Authors: Jatinder S. Minhas, Amit K. Mistri Tags: Letter to the Editor Source Type: research
Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study
ConclusionsApixaban therapy is associated with a significantly reduced risk of bleeding compared to phenprocoumon. Bleeding risk with dabigatran was similar to that of phenprocoumon but bleeding risk with rivaroxaban was higher.
Source: Clinical Research in Cardiology - March 13, 2017 Category: Cardiology Source Type: research
Comparison of the cost-utility of direct oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in Spain.
CONCLUSIONS: All three direct anticoagulants are cost-effective against acenocoumarol. Dabigatran is economically dominant over rivaroxaban and apixaban in the Spanish setting, as it is more effective and cheaper.
PMID: 28272725 [PubMed - in process]
Source: Revista de Neurologia - March 9, 2017 Category: Neurology Authors: Monreal-Bosch M, Soulard S, Crespo C, Brand S, Kansal A Tags: Rev Neurol Source Type: research
Patients' experiences of atrial fibrillation and non-vitamin K antagonist oral anticoagulants (NOACs), and their educational needs: A qualitative study
This study explores patients' experiences of dabigatran and their recommendations for development of educational materials.
Source: Thrombosis Research - March 6, 2017 Category: Hematology Authors: Danielle E Clarkesmith, Gregory Y H Lip, Deirdre A Lane Tags: Full Length Article Source Type: research
Gastrointestinal Bleeding and Direct Oral Anticoagulants Amongst Patients With Atrial Fibrillation in the “Real World”
The pivotal aim of oral anticoagulation in atrial fibrillation (AF) is prevention of AF-related thromboembolic strokes. The vitamin K antagonists (eg, warfarin) have been the standard of care for many years, reducing both stroke and mortality rates by 64% and 26% respectively, compared with placebo/control.1 Approval and market release of direct oral anticoagulants (DOACs; also referred to as non-vitamin K antagonist oral anticoagulants2), such as dabigatran, rivaroxaban, apixaban, and edoxaban, have changed the landscape of thromboprophylaxis substantially.
Source: Gastroenterology - February 28, 2017 Category: Gastroenterology Authors: Micha ł Mazurek, Gregory Y.H. Lip Tags: Editorial Source Type: research
Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system
AbstractNon vitamin K oral anticoagulants (NOACs) do not require regular monitoring but information about their pharmacodynamic effect may be importantin situations like trauma, stroke oremergent surgery. Currently, no standardized point-of-care test is available to evaluate the anticoagulant effects of NOACs. We evaluated the anticoagulant effect of NOACs with the next generation point-of-care TEG assay (TEG ® 6S) based on a fully-automated thrombelastography system. We used two TEG® 6S assays, the DTI assay and Anti-Factor Xa (AFXa) assay, to detect anticoagulant effects and classify NOACs. Blood from healthy volunteer...
Source: Journal of Thrombosis and Thrombolysis - February 27, 2017 Category: Hematology Source Type: research
Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation
This study aimed to evaluate the effects of changing from warfarin to rivaroxaban on bone mineral metabolism, vascu lar calcification, and vascular endothelial dysfunction. We studied 21 consecutive patients with persistent or chronic AF, who were treated with warfarin at least for 12 months. Warfarin administration was changed to rivaroxaban (10 or 15 mg/day) in all patients. Osteopontin (OPN), bone alkaline ph osphatase (BAP), and under-carboxylated osteocalcin (ucOC) were measured. Pulse wave velocity (PWV) and augmentation index (AI) were also measured as atherosclerosis assessments. All measurements were done before ...
Source: Heart and Vessels - February 22, 2017 Category: Cardiology Source Type: research
Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases
We report 11 real-life clinical cases in which idarucizumab was used after multidisciplinary consultation in a variety of emergency situations including severe postoperative bleeding, emergency high-bleeding-risk surgery (hip/spine surgery and neurosurgery), invasive diagnostic testing (lumbar puncture), intracranial bleeding (pre-pontine subarachnoid hemorrhage and lobar intracerebral hemorrhage) and thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke. This case series illustrates the role of idarucizumab in improving patient safety in rare emergency situations requiring rapid reversal of ...
Source: Journal of Thrombosis and Thrombolysis - February 15, 2017 Category: Hematology Source Type: research
Reversal of Direct Oral Anticoagulants: Current Status and Future Directions
Semin Respir Crit Care Med 2017; 38: 040-050 DOI: 10.1055/s-0036-1597831Direct oral anticoagulants (DOACs) are increasingly used for prevention and treatment of venous thromboembolism and for prevention of stroke in patients with nonvalvular atrial fibrillation. In phase III clinical trials that included more than 100,000 patients, the DOACs were at least as effective as vitamin K antagonists (VKAs) and were associated with less serious bleeding, particularly less intracranial bleeding. Real-world evidence supports these outcomes. Despite this, some physicians and patients are concerned about serious bleeding or emergencie...
Source: Seminars in Respiratory and Critical Care Medicine - February 15, 2017 Category: Respiratory Medicine Authors: Weitz, Jeffrey I. Tags: Review Article Source Type: research
